Attached files
| file | filename |
|---|---|
| 8-K - ORCHID CELLMARK INC--FORM 8-K - ORCHID CELLMARK INC | d8k.htm |
 Fourth Quarter and Year-End 2009 Earnings Conference Call March 11, 2010 Fourth Quarter and Year-End 2009 Earnings Conference Call March 11, 2010 Exhibit 99.1 |
 Forward-Looking Statement Forward-Looking Statement All statements in this presentation that are not historical are forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to the
implementation of government contracts, growing through acquisitions,
the potential value of the “mega tender”, our potential success in the U.K. National Procurement Plan, expansion of our U.K. facilities, the opportunity for work related to
all-arrestee legislation, the potential of property crime testing,
consolidation of our US forensic and paternity facilities, operating
efficiencies, technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid Cellmark’s products and services, dependence on government
funding, competition, intellectual property of others, patent protection,
litigation, and the timing and amount of contracts put up for bid. These
risks and other additional factors affecting these statements and Orchid Cellmark’s business are discussed under the headings “Risks Related to Our Business” and “Risks Associated with Our Common Stock” in Orchid Cellmark’s Annual Report on Form 10-K for the year ended December 31, 2008, as amended, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Securities and Exchange Commission from time to time. Orchid Cellmark expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid Cellmark’s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law. |
 Total
Annual Revenue Trend - Constant Dollars (in 000’s - unaudited) Total Annual Revenue Trend - Constant Dollars (in 000’s - unaudited) Note: All revenues calculated using 2008 Fx rates 56,000 58,000 60,000 62,000 64,000 66,000 2006 2007 2008 2009 |
 Historical Annual Net Loss (in 000’s) Historical Annual Net Loss (in 000’s) (12,000) (10,000) (8,000) (6,000) (4,000) (2,000) 0 2004 2005 2006 2007 2008 2009 |
 EBITDA (in 000’s - unaudited) EBITDA (in 000’s - unaudited) (8,000) (6,000) (4,000) (2,000) 0 2,000 4,000 2006 2007 2008 2009 |
 Cash
Flow From Operations (in 000’s) Cash Flow From Operations (in 000’s) (12,000) (10,000) (8,000) (6,000) (4,000) (2,000) 0 2,000 4,000 2006 2007 2008 2009 |
 U.S.
Laboratories U.S. Laboratories Dallas Forensics Dayton Paternity E.Lansing Paternity Nashville Forensics |
 U.S.
Laboratories U.S. Laboratories Dallas Forensics Dayton Paternity Consolidation Consolidation Estimated Annual Cost Savings of $2.4 Million |
 U.K.
Regional Laboratories U.K. Regional Laboratories Abingdon HQ Chorley Facility Orchid Orchid |
 U.S.
Sexual Assault Kit Casework Backlog Will Continue To Grow U.S. Sexual Assault Kit Casework Backlog Will Continue To Grow Orchid Cellmark has contracts with all four of the above agencies and has just received the first of the Houston PD rape kit backlog Orchid Cellmark has contracts with all four of the above agencies and has just received the first of the Houston PD rape kit backlog • A Senate hearing to discuss mechanisms for the federal government to help alleviate the
rape kit backlog was held in December. – During the hearing, S. 2736 (Justice for Survivors of Sexual Assault Act of 2009), a
bill to reduce the national rape kit backlog and clear the thousands of
existing untested rape kits in police and crime-lab storage facilities.
– Orchid Cellmark supplied written testimony at the hearing as to how private labs can
contribute to eliminating the backlog – The House is now putting together a companion bill for S. 2736 • At the state level, pressure from victims groups and the recent CBS news reports on the
rape kit backlog is driving significant activity to address this backlog in
many states. – The Michigan State Police have identified as many as 12,000 rape kits that need to be tested and the Michigan legislature has held formal hearings to determine how to proceed
– Illinois has legislation pending that requires that all rape kits be tested including
those currently in storage (precise numbers are unknown) – The Birmingham (AL) police department identified 2,100 rape kits in storage – The Houston police department has identified 4,000 rape kits that need to be tested and
have begun the testing process – Several other cities were identified by CBS as having a significant number of untested
rape kits |
 U.K. Revenue U.K. Revenue £0 £2,000 £4,000 £6,000 £8,000 £10,000 £12,000 £14,000 £16,000 £18,000 £20,000 2006 2007 2008 2009 2009+ Last year of FAL revenue NW/SW Award NW/SW Tender submitted Kent, Sussex & City of London Awards 1 st full year of NW/SW Award plus other Forensics Drives Growth |
 |